OncoMatch/Clinical Trials/NCT06787144
ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
Is NCT06787144 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies ELVN-001 for cml (chronic myelogenous leukemia).
Treatment: ELVN-001 — The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in Japanese patients with chronic phase chronic myeloid leukemia with and without T315I mutations in patients who has failed, or the patient is intolerant to, or not a candidate for, at least 2 prior TKIs.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Chronic Myeloid Leukemia
Biomarker criteria
Required: BCR fusion
BCR::ABL1 positive CP-CML
Required: ABL1 fusion
BCR::ABL1 positive CP-CML
Disease stage
Required: Stage CHRONIC PHASE
CP-CML
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: BCR-ABL inhibitor
failed, or the patient is intolerant to, or not a candidate for, at least 2 prior TKIs
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Adequate hematologic, hepatic and renal function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06787144 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received BCR-ABL inhibitor.
Does this trial require BCR?
Yes, BCR fusion is a required biomarker for enrollment.
Does this trial require ABL1?
Yes, ABL1 fusion is a required biomarker for enrollment.
What disease stage is eligible?
Stage CHRONIC PHASE is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify